Research ArticleOncology
Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy
Jingjing Zhang, Qingxing Liu, Aviral Singh, Christiane Schuchardt, Harshad R. Kulkarni and Richard P. Baum
Journal of Nuclear Medicine November 2020, 61 (11) 1560-1569; DOI: https://doi.org/10.2967/jnumed.119.241414
Jingjing Zhang
1Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany
Qingxing Liu
1Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany
2Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; and
Aviral Singh
1Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany
3GROW–School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands
Christiane Schuchardt
1Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany
Harshad R. Kulkarni
1Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany
Richard P. Baum
1Theranostics Center for Molecular Radiotherapy and Precision Oncology, ENETS Center of Excellence, Zentralklinik Bad Berka, Bad Berka, Germany

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 61, Issue 11
November 1, 2020
Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy
Jingjing Zhang, Qingxing Liu, Aviral Singh, Christiane Schuchardt, Harshad R. Kulkarni, Richard P. Baum
Journal of Nuclear Medicine Nov 2020, 61 (11) 1560-1569; DOI: 10.2967/jnumed.119.241414
Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy
Jingjing Zhang, Qingxing Liu, Aviral Singh, Christiane Schuchardt, Harshad R. Kulkarni, Richard P. Baum
Journal of Nuclear Medicine Nov 2020, 61 (11) 1560-1569; DOI: 10.2967/jnumed.119.241414
Jump to section
Related Articles
Cited By...
- Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors
- Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of 177Lu-DOTATATE PRRT: Does In Vivo Molecular PET Perform Better from the Viewpoint of Prediction of Tumor Biology?
- Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
- 18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study